Is uniQure N.V. (QURE) a Buy, Sell, or Hold?
uniQure N.V.
NASDAQ:QURE
$41 USD
-$0.52 (-1.25%)
- Volume
- 903.09K
- Average Volume
- 2.2M
- Market Capitalization
- $2.79B
- P/E Ratio
- -11.68
- Dividend Yield
- 0.00%
- Price Target
- $63.00
- Year High
- $71.50
- Year Low
- $8.73
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.40
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Matthew Kapusta |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | QURE |
| CUSIP | N9028A108 |
| CIK | 0001590560 |
| Web | https://www.uniqure.com |
| Phone | 31 20 240 6000 |
| Currency | USD |
| Employees | 221 |
| Country | NL |
Liquidity
| Debt-to-Equity Ratio | 0.42 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.40 |
| Quick Ratio | 10.40 |
| Cash Ratio | 2.36 |
Sales & Book Value
| Annual Sales | $16.1M |
| Price / Sales | 154.12 |
| Cash Flow | -2.74 |
| Price / Cash Flow | -16.20 |
| Price / Book | 17.23 |
Price Target and Rating
| Average Stock Price Forecast | $63.00 |
| High Stock Price Forecast | $80.00 |
| Low Stock Price Forecast | $28.00 |
| Forecast Upside/Downside | -34.92% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 37 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.46 |
| Trailing P/E Ratio | -11.68 |
| PEG Ratio | -0.70 |
| P/E Growth | -0.70 |
| Net Income | $-198.97M |
| Net Margin | -1154.42% |
| Pretax Margin | -1123.34% |
| Return on Equity | -145.81% |
| Return on Assets | -26.82% |
Financials Score
| AltmanZ Score | 0.46 |
| Piotroski Score | 3.00 |
| Working Capital | 556.55M |
| Total Assets | 778.71M |
| Ebit | -142.33M |
| Market Cap | 2.8B |
| Total Liabilities | 629.36M |
Poll Results
About uniQure N.V. (NASDAQ:QURE) Stock
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement wi ... th Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
2026-07-01 10:55:17
uniQure N.V. (QURE) reached a significant support level, and could be a good pick for investors from a technical perspective.
2026-06-25 16:10:00
LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.
uniQure Announces Pricing of Upsized $225 Million Public Offering
2026-06-23 21:13:00
LEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $225 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 741,758 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about June 25, 2026, subject to the satisfaction of customary closing conditions.
uniQure Announces $150 Million Proposed Public Offering
2026-06-22 16:01:00
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its ordinary shares on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
2026-06-22 11:31:24
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
2026-06-19 15:20:32
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
2026-06-19 07:05:00
~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~
UniQure: AMT-130's FDA Path Reaffirms My Bull Case
2026-06-18 10:06:55
QURE is now a more credible Huntington's disease gene-therapy story after the FDA reopened a near-term BLA path for AMT-130. The main bet is that AMT-130 could eventually become the first approved disease-modifying therapy for Huntington's disease. Also, QURE's balance sheet gives management time to pursue that BLA for AMT-130.
Frequently Asked Questions
-
What is the current uniQure N.V. (QURE) stock price?
-
uniQure N.V.(NASDAQ:QURE) stock price is $41 in the last trading session. During the trading session, QURE stock reached the peak price of $71.5 while $8.73 was the lowest point it dropped to. The percentage change in QURE stock occurred in the recent session was --1.25% while the dollar amount for the price change in QURE stock was -$-0.52.
-
QURE's industry and sector of operation?
-
The NASDAQ listed QURE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of QURE?
-
Walid Abi-Saab | Chief Medical Officer
Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site
Richard Porter | Chief Business & Scientific Officer
Chiara Elizabeth Russo | Senior Director of Investor Relations
Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary -
How many employees does QURE have?
-
Number of QURE employees currently stands at 221. QURE operates from Paasheuvelweg 25, Amsterdam, NH 1105 BP, NL.
-
Link for QURE official website?
-
Official Website of QURE is: https://www.uniqure.com
-
How do I contact QURE?
-
QURE could be contacted at phone #31 20 240 6000 and can also be accessed through its website. QURE operates from Paasheuvelweg 25, Amsterdam, NH 1105 BP, NL.
-
How many shares of QURE are traded daily?
-
The average number of QURE shares traded daily for last 3 months was 2.2M.
-
What is the market cap of QURE currently?
-
The market value of QURE currently stands at $2.79B with its latest stock price at $41